-transparent.png){kind=logo}
DNA-mediated gene transfer was used to introduce DNA from a methotrexate-resistant mouse fibroblast cell line into mouse bone marrow cells. This cell line contained a methotrexate-resistant dihydrofolate reductase, active at 10(-4) M methotrexate, which was electrophoretically separable from the wild-type mouse enzyme. Transformed hematopoietic cells were returned to irradiated mice and selected in vivo by methotrexate administration. Some recipients of transformed marrow cells expressed the electrophoretically distinct, methotrexate-resistant dihydrofolate reductase in hematopoietic cells. These observations suggest that successful transformation of marrow stem cells to methotrexate resistance is accomplished by insertion of a dihydrofolate reductase gene coding for a mutant enzyme that is highly resistant to methotrexate.
M Bar-Eli, and
H D Stang, and
K E Mercola, and
M J Cline
January 1989,
Developmental genetics,
M Bar-Eli, and
H D Stang, and
K E Mercola, and
M J Cline
May 1992,
Mutation research,
M Bar-Eli, and
H D Stang, and
K E Mercola, and
M J Cline
April 2000,
Anti-cancer drugs,
M Bar-Eli, and
H D Stang, and
K E Mercola, and
M J Cline
January 1996,
Gene expression,
M Bar-Eli, and
H D Stang, and
K E Mercola, and
M J Cline
March 1985,
The Journal of biological chemistry,
M Bar-Eli, and
H D Stang, and
K E Mercola, and
M J Cline
May 1974,
The Journal of biological chemistry,
M Bar-Eli, and
H D Stang, and
K E Mercola, and
M J Cline
March 1982,
Molecular and cellular biology,
M Bar-Eli, and
H D Stang, and
K E Mercola, and
M J Cline
February 1982,
Journal of cellular physiology,
M Bar-Eli, and
H D Stang, and
K E Mercola, and
M J Cline
March 1982,
Molecular pharmacology,
M Bar-Eli, and
H D Stang, and
K E Mercola, and
M J Cline
February 2009,
Molecular cancer therapeutics,
